Prematurity and Genetic Liability for Autism Spectrum Disorder

Yali Zhang[1,2], Ashraf Yahia[1,2], Sven Sandin[3,4,5], Ulrika Åden[6,7,8] and Kristiina Tammimies[1,2*]

[1]Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Department of
Women's and Children's Health, Karolinska Institutet
[2]Astrid Lindgren Children's Hospital, Karolinska University Hospital, Region Stockholm, Stockholm,
Sweden
[3]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
[4]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
[5]Seaver Center for Research and Treatment at Mount Sinai, New York, USA
[6]Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
[7]Department of Neonatology, Division of Neonatal Medicine, Karolinska University Hospital,
Stockholm, Sweden
[8]Department of Bioclinical sciences, Linköping University, Linköping, Sweden

15   Abstract

Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by

diverse presentations and a strong genetic component. Environmental factors, such as prematurity,

have also been linked to increased liability for ASD, though the interaction between genetic

predisposition and prematurity remains unclear. This study aims to investigate the impact of genetic

liability and preterm birth on ASD conditions.

Methods: We analyzed phenotype and genetic data from two large ASD cohorts, the Simons

Foundation Powering Autism Research for Knowledge (SPARK) and Simons Simplex Collection (SSC),

encompassing 78,559 individuals for phenotype analysis, 12,519 individuals with genome

sequencing data, and 8,104 individuals with exome sequencing data. Statistical significance of

differences in clinical measures was evaluated between individuals with different ASD and preterm

status. We assessed the rare variants burden using generalized estimating equations (GEE) models

and polygenic load using ASD-associated polygenic risk score (PRS). Furthermore, we developed a

machine learning model to predict ASD in preterm children using phenotype and genetic features

available at birth.

Results: Individuals with both preterm birth and ASD exhibit more severe phenotypic outcomes

despite similar levels of genetic liability for ASD across the term and preterm groups. Notably,

preterm ASD individuals showed an elevated rate of de novo variants identified in exome sequencing

(GEE model, p=0.005) in comparison to the non-ASD preterm group. Additionally, a GEE model

showed that a higher ASD PRS, preterm birth, and male sex were positively associated with a higher

predicted probability for ASD, reaching a probability close to 90% in SPARK. Lastly, we developed a

machine learning model using phenotype and genetic features available at birth with limited

predictive power (AUROC = 0.65).

Conclusions: Preterm birth may exacerbate the multimorbidity present in ASD, which was not due to

the ASD genetic factors. However, increased genetic factors may elevate the likelihood of a preterm

child being diagnosed with ASD. Additionally, a polygenic load of ASD-associated variants had an

additive role with preterm birth in the predicted probability for ASD, especially for boys. We propose

that incorporating genetic assessment into neonatal care could benefit early ASD identification and

intervention for preterm infants.

Keywords: Prematurity, Autism Spectrum Disorder, Genetics, Polygenic risk score, Machine learning,

Generalized estimating equations model.

Introduction

Introduction

Autism Spectrum Disorder (ASD) is an early-onset neurodevelopmental condition characterized by

challenges in social interaction, communication, and restrictive and repetitive behaviors and interests

[1]. In addition to these core symptoms, individuals with ASD have multiple co-occurring

neurodevelopmental, psychiatric, and physical conditions, which contribute to clinical heterogeneity

[2].

The etiology of ASD is multifaceted and not yet fully elucidated [3,4]. However, genetic factors

account for up to 80-90% of the liability for ASD [4–6]. Rare de novo variants (DNV), especially those

affecting the gene function of constraint genes, are shown to be enriched in ASD [7,8]. Rare inherited

variants in ASD-related genes are also shown to be overtransmitted from parents to their children

with ASD [5,9]. In addition to rare variants, genome-wide association studies (GWAS) have identified

a few common variants associated with ASD, and the polygenic load calculated using polygenic risk

score (PRS) has demonstrated predictive ability for ASD and ASD traits [10,11], explaining 2% of

variance in ASD status [12]. Furthermore, ASD PRS can uniquely predict variability in cognitive

performance [11].

In addition to genetic factors, there are several environmental factors associated with ASD [3]. The

most robustly associated environmental stressor is prematurity, with ASD likelihood in preterm about

two to four folds higher than in term, and ASD likelihood increasing as gestational age at birth

decreases [13,14]. Although preterm birth involves both genetic and environmental components

[15], it is typically discussed as an environmental factor in ASD studies [3,16]. Preterm birth, defined

as delivery with gestational age before 37 weeks, can be further categorized into four preterm sub-

categories: extremely preterm (<28 weeks), very preterm (28-31 weeks), moderate preterm (32-33

weeks), and late preterm (34-36 weeks). Prematurity is not only associated with ASD but also with

neurocognitive development and other health outcomes [17–19]. Earlier studies investigating

phenotypes in children with ASD suggested that extremely or very preterm ASD children have more

language deficits and developmental delays compared to term ASD children [20,21]. However, others

reported that no significant differences in development were found when studying the entire

preterm group [22]. Moreover, preterm birth as an exposure is associated with various comorbidities

in ASD, including attention and behavioral problems, neurological disorders, and growth deficiency.

However, more investigations are needed to understand ASD phenotypic spectrum in preterm and

term birth as well as how different sub-groups of prematurity contribute to specific medical

outcomes and traits.

Interestingly, preterm infants have been found to have increased DNV rates compared to term [23],

and various de novo copy number variations (CNVs) in preterm were found related to

neurodevelopmental disorders genes (NDD genes) [24], but it remains uncertain whether DNV

burden is further elevated when both ASD and preterm birth are present. Moreover, the relationship

between ASD polygenic load and prematurity has only been evaluated by Cullen et al based on

cognition, but no interaction was found between ASD PRS and gestational age at birth [16].

Furthermore, there are indications that a small fraction of preterm individuals would have

recognizable genetic disorders [25]. However, there have not been specific studies focusing on

genetic factors within preterm individuals and ASD.

While genetic and phenotypic studies on the population level are informative, these analyses may

miss interactions and non-linear relationships within or between factors on an individual level. To

address this complexity, machine learning (ML) has the potential to identify patterns in high-

dimensional data that traditional statistical methods may overlook, aiding in prediction. To date, ML

prediction models have emerged to predict ASD using different data sources, such as routine medical

assessments and electronic records [26,27], genetic data [28], and integrative models [29]. However,

none of the published ML models currently predict ASD in preterm children. In the existing ML

models for ASD prediction, included features are typically collected when the child is at least 1-2

years of age or older [26,30]. It remains unclear whether integrating phenotype and genetic

information available at birth could enable earlier ASD identification in preterm infants.

In this study, we aimed to enhance our understanding of ASD in preterm children by analyzing both

clinical and genetic data in two large ASD cohorts, the Simons Foundation Powering Autism Research

for Knowledge (SPARK) [8,31], and the Simons Simplex Collection (SSC) [32]. Across individuals with

different ASD and prematurity sub-groups, we first examined their phenotype severity through the

prevalence and multimorbidity of other medical diagnoses. Thereafter, we assessed the burden of

rare and common sequence-level variants. Finally, we built an ML model using both phenotype and

genetic features that could be obtained at birth to predict ASD in preterm individuals.

Methods

Study cohorts

The Simons Foundation Powering Autism Research for Knowledge (SPARK) database, initiated by the

Simons Foundation Autism Research Initiative (SFARI), recruited families in the USA with one or

more children diagnosed with autism spectrum disorder (ASD) [31]. We utilized demographic and

phenotype data from the SPARK collection version 9 with a release date 2022-12-12. We considered

medical and psychiatric diagnosis history from the basic medical screen dataset, grouping specific

diagnoses into nine diagnostic categories: behavior, development, mood, growth, birth, eating

habits (Eat), neurological conditions (Neuro), visual and auditory impairments (Visaud), and sleep.

This dataset includes 9,196 individuals with ASD and born preterm with gestational age less than 36

weeks (ASD-preterm), 65,021 individuals with ASD and born term (ASD-term), and 2,706 individuals

without ASD and born preterm (non-ASD-preterm). We also stratified preterm individuals into four

sub-groups based on gestational age: extremely preterm (<28 weeks), very preterm (28-31 weeks),

moderate preterm (32-33 weeks), and late preterm (34-36 weeks). Additionally, we compared

quantitative measures using the Child Behavior Checklist (CBCL) t-score for 1 to 5 and 6 to 18 years

of age, Developmental Coordination Disorder Questionnaire (DCDQ) final score, Repetitive Behavior

Scale-Revised (RBS-R) total final score, Social Communication Questionnaire (SCQ) final score and

Full-Scale Intelligence quotient (FSIQ) score. Additional file 1: Tables S1 and S2 provide detailed

description of the specific diagnoses and quantitative measures.

For the genetic part, dataset SPARK genome sequencing (GS) version 1.1 variant calling was used,

including 12,519 individuals from 3,394 families, with 315 ASD-preterm, 2,788 ASD-term, and 155

non-ASD-preterm individuals. We also utilized earlier published DNV data from exome sequencing

(ES) to calculate the event rate [8]. Among the 6,444 ASD individuals with DNV information, 5,747

were born full-term, and 697 were born preterm. Furthermore, DNV information was accessible for

210 preterm children without ASD.

We also used the Simons Simplex Collection (SSC) cohort. SSC recruited more than 10,000 individuals

from 2,000 families [32]. Due to the absence of preterm information for non-ASD individuals

(siblings of ASD probands), we only conducted studies for ASD-preterm and ASD-term groups. After

excluding individuals with unreliable gestational age, unknown ASD diagnosis, births occurring post-

term (gestational age > 40 weeks), and missing outcomes information, we retained 1,637 probands

diagnosed with ASD (157 preterm and 1,479 term) for the diagnostic category analysis. Additionally,

we analyzed available quantitative measures, including CBCL score, DCDQ score, SCQ score, and IQ

score. Detailed descriptions of specific diagnoses and qualitative measures are provided in

Additional file 1: Tables S3 and S4. We incorporated the de novo variants (DNV) dataset from Ng et

al in our analysis, encompassing 1,450 ASD individuals after excluding post-term births [33].

Additionally, the Polygenic Risk Score (PRS) dataset we used sourced from Weiner et al comprised

1,590 ASD individuals, excluding post-term births [34].

De novo variant calling and analysis

In SPARK, GS was conducted on the Illumina NovaSeq 6000 system. Variant calling was performed

using GATK (v3.5) with HaplotypeCaller, and all samples were jointly called by GLnexus (v1.4.1). To

find de novo variants (DNV) of children, we included all trios. For families with more than one child,

each child forms a trio with their parents, resulting in multiple trios within the same family. There

were 5,712 trios from 3,364 families. We used two tools, Slivar (v0.2.8) and GATK (v4.1.4.1), to call

the DNV from SPARK trios, and true DNV was selected when it was found in both tools [35,36]. The

DNV was called if it was labeled as "denovo" with allele balance (AB) in children higher than 0.25 in

Slivar and identified as high confidence DNV in GATK. For pseudo-autosomal regions on the sex

chromosome, we separately considered the variant genotype as 1/0 in children. We did not find

DNVs on chrY in pseudo-autosomal regions. Then, we did quality control to further filter the rare

DNV by removing variants with GQ<20, DP<10, gnomAD population allele frequencies > 0.001, and

variants of either 10 A's or T's in a row. We filtered out DNVs on genomic centromeres and low

complex regions. Then we removed DNV if 1) it can be found in other family's parents, 2) it can be

found in only children but more than three families, and 3) it on positions having more than 3 multi-

alleles. We identified 432,903 DNVs, including 16,155 exonic DNVs and 986 loss-of-function (LOF)

variants. We filtered out 29 children with DNV counts beyond three times the standard deviation

from the mean DNV count. Based on these criteria, the average number of rare DNVs per child was

75.9.

We annotated DNVs by ANNOVAR (v2020.06.08) with buildver as hg38 and protocol as ljb26_all,

SnpEff (v5.2) with GRCh38.105 databases, and VEP (v110) with assembly as GRCh38 and 154 dbSNP

[37–39]. DNVs with Sequence Ontology (SO) terms as "frameshift", "splice_acceptor",

"splice_donor", "start_lost", "stop_gained", and "stop_lost" in gene effect were considered as LOF

DNV. Additionally, we identified variants on the neurodevelopmental disorder-related genes (NDD

gene) using high-confidence ASD genes collected by the Simons Foundation Autism Research

Initiative (SFARI) (2024-01-16 release) with gene scores of 1 or 2 and labeled as syndromic and green

gene list of Intellectual disability - microarray and sequencing (Version 5.497) on Genomics England

PanelApp (2024-03-14 accessed) (Additional file 2) [40,41].

Inherited variants calling

Using the same GS data as for DNV calling, including 5,712 trios from 3,364 families, we extracted

variants on the genomic protein-coding NDD genes (Additional file 2) using VCFtools (v0.1.16) [42].

Then we annotated the inheritance mode of NDD genes using the ID gene panel app, SysNDD

database (v0.1.0) and DDgenes [41,43,44]. There were 80% (1625 genes) of NDD genes annotated,

including 738 dominant genes coded as monoallelic or dominant, and 944 recessive genes coded as

biallelic or recessive in databases (Additional file 2). To restrict the analysis to rare inherited variants,

we used the allele frequency filter threshold of 0.001 and 0.01 for dominant and recessive genes,

respectively. Variants with GQ<20, DP<10, and genotypes conflicting with the inheritance mode of

located genes were filtered out. We did not find compound variants (more than 1 heterozygous

variant on the same recessive gene for one child). For variants on dominant genes, we identified LOF

following the same process in the DNV part and found damaging missense variants met at least one

of the following conditions: CADD>=20, SIFT labeled as D, POLYPHEN labeled as P and D,

PHYLOP>=2.0 or REVEL>=0.5. From 5,712 trios in the SPARK GS database, we identified 245,671 and

4,346 inherited variants in dominant and recessive NDD genes, respectively. We identified 2,717 LOF

and 39,136 damaging missense variants in genes with a dominant inheritance mode.

Polygenic risk score

Based on GS jointly called variants from 12,519 SPARK participants, we performed quality control for individuals and variants using PLINK1.9 with parameters listed in Additional file 1: Table S5, retaining 11,933 individuals and 9,558,997 variants with a total genotyping rate of 99.9% [45]. Then, genome coordinates of variants were converted from hg38 to hg19 using liftOver (v2017-03-14) [46], and 9,428,216 were mapped after removing duplicated variants. We calculated the posterior SNP effect size estimates using PRS-CS with ASD GWAS summary statistics from the Psychiatric Genomics Consortium (November 2017 release) (46,351 individuals) and European LD reference data from 1000 Genome phase III [10,47]. The default parameters used in PRS-CS also be listed in Additional file 1: Table S5. The final PRS was calculated using the score function in PLINK1.9 with the estimated posterior SNP effect size. To minimize the effects on different populations, we analyzed the ancestry of individuals using Principal component analysis (PCA) by pca command in PLINK1.9. The ten principal components (PC1-10) were included as covariates when we calculated the association between phenotype and PRS.

Statistical analysis

All analyses were performed using R programming language (v4.2.2). Commencing with an exploration of phenotypes, we investigated two pairs of groups: preterm and term birth within individuals diagnosed with ASD (ASD-preterm versus ASD-term); and individuals diagnosed with ASD to those without ASD within preterm birth (ASD-preterm versus non-ASD-preterm). An individual was considered to possess the diagnosis feature if any specific diagnosis within that diagnostic category was exhibited, no matter how many specific diagnoses there were at the same time.

In phenotypic analysis, the prevalence is reported by the frequency of individuals with the diagnostic

categories (Additional file 1: Table S1). We examined the differences in prevalence between ASD-

preterm and ASD-term, ASD-preterm and non-ASD-preterm using odds ratios (ORs) with 95%

confidence interval (CI) and statistical significance reported by FDR-adjusted p-values. After

stratifying preterm stages, we used χ^2 test to evaluate differences across preterm stages, post-hoc

comparisons for each pair of preterm stages, and Kendall's tau test to examine rank correlation of

preterm stages with prevalences. Then, prevalences and ORs of multimorbidity (one, two, three,

four, or not less than five diagnostic categories; Additional file 1: Tables S1) were estimated by ASD

and preterm status, and prevalence differences in multigroup were examined by χ^2 test. We also

examined prevalence and multimorbidity ORs adjusted for sex and age using generalized estimating

equation (GEE) models, with family ID as a clustering variable. GEE model is more robust to

assumptions of data following a particular data distribution and adjusts for correlations between

individuals, e.g., siblings and families [48]. Additionally, we examined differences in quantitative

measures using the 2-sided Wilcoxon rank sum test for pairwise comparisons and in multiple

comparisons using the Kruskal-Wallis rank sum test. To account for multiple testing, we applied false

discovery rate correction to p-values.

The burden of DNV and inherited variants was evaluated by comparing rates of such variants in each

subgroup categorized by ASD and preterm status. We assessed the statistical differences between

groups through GEE models with Poisson family, sex as a covariate, and family ID as a clustering

variable. PRSs were z-standardized and statistical significance for PRS distribution was reported by

the 2-sided Wilcoxon rank sum test. The association between targeted phenotype (y/n) and PRS in

each subgroup was also evaluated in GEE logistic model with sex(m/f) and PC1-10 from ancestry

checking as covariates.

The variance of ASD status explained by PRS in the SPARK cohort was quantified using the McFadden

Pseudo-r^2 value based on the logistic regression model adjusted for sex and ancestry PC1-10. To

examine the associations between ASD diagnosis and possible variables, we modeled the probability

of ASD (y/n) by fitting GEE logistic model(s) with the equation as [ASD (y/n) ~ sex (m/f) + preterm

(y/n) + standardized PRS] and family ID as a clustering variable in European population to find the

correlation between ASD diagnosis and possible variables. To visualize the predicted probabilities of

ASD from the GEE logistic model, we utilized ggemmeans function in ggeffects R package (v1.5.1)

[49], showing the average predicted probabilities of ASD for specific levels of variables adjusted for

other covariates in the model. After that, the variable (preterm (y/n) * standardized PRS) was added

to the GEE logistic model to check the correlation between ASD (y/n) and the interaction of preterm

status and PRS. To detect the association between multimorbidity and DNV burden, GEE models

(Table S4) and linear regression were used.

Machine learning model

This part of the analysis was performed in R (v4.2.2). Within preterm individuals, we utilized non-

ASD and ASD diagnoses as two classification flags, incorporating features obtained from data that

can be collected at birth. For phenotypical variables, we included birth complications, sex, and birth-

related conditions. Genetic variables encompassed the count of several types of genetic variants, the

CADD score of de novo variants (DNV), and the PRS of ASD. To remove redundant variables and

identify informative features, we employed the Recursive Feature Elimination (RFE) algorithm [50].

RFE is a feature selection technique that iteratively removes the least important features based on

model performance, refitting the model with the remaining features until the optimal subset of

features is identified. In RFE, we utilized random forest function and 10-fold cross-validation in the

underlying model to assess feature importance throughout the process. For the features selected

after RFE, we only retained the more general feature (e.g., retaining LOF over LOF on NDD genes) in

any pair of features with a correlation coefficient above 0.7 to reduce multicollinearity. The details

of selected features are listed in Additional file 1: Table S6.

We applied R package caret (v6.0-94) [51] to train the ML models. Given the limited sample size and

the higher proportion of ASD samples than non-ASD, we conducted nested cross-validation (NCV)

and hyperparameter tuning with grid search to enhance model performance. In NCV, we partitioned

the data into 10 folds in the outer loop, with nine folds used for training and the remaining fold for

testing. Within the inner loop, we performed repeated 10*10-fold cross-validation, and the model

with the best performance was applied to the outer loop. We employed three algorithms—Extreme

Gradient Boosting (XGBoost), Random Forest (RF), and Linear Support Vector Machine (SVM)—to

construct the models. The values of hyperparameter tuning for each model are detailed in

Additional file 1: Table S7. We reported evaluation metrics, including accuracy with a 95% CI, area

under the receiver operating characteristic curve (AUROC), specificity, sensitivity, and F1-score.

Moreover, the SHapley Additive exPlanations (SHAP) values for features were computed and

visualized using the R package SHAPforxgboost (v0.1.3) [52], quantifying the contribution of each

feature to individual model predictions in terms of direction and magnitude.

Result

Phenotype comparison across ASD and prematurity

We utilized basic medical screening data from 181,248 individuals in the SPARK version 9 cohort

(release date 2022-12-12). Among them, 74,217 (41%) were diagnosed with ASD, and 11,902 (7%)

were born preterm. When performing phenotype comparison, we grouped individuals with 9,196

individuals with ASD and being preterm (ASD-preterm), 65,021 individuals with ASD but being term

(ASD-term), and 2,706 preterm individuals without ASD diagnosis (non-ASD-preterm) (Figure 1, Table

). In the SSC cohort, gestational age records were available only for probands with ASD, of which

157 were preterm and 1,479 were term. We stratified the preterm stage based on gestational age at

birth (Table 1).

311
Figure 1. Overview design of the study. Firstly, we performed phenotype analysis on diagnosis
prevalence, burden of multimorbidity and quantitative measures in the SPARK cohort. The sample
size of SPARK is shown in the Venn diagram, with blue indicating ASD, pink indicating preterm with
unknown gestational age, and green indicating preterm with known gestational age. Secondly, we
analyzed the de novo variant and inherited variant burden, separately, focusing on loss-of-function
variants and damaging missense and if these affected neurodevelopmental disorder (NDD) genes.
Additionally, we utilized polygenic risk scores for common variants associated with ASD. For
validation, we applied similar analyses in the SSC cohort. Thirdly, we integrated phenotype and
genomic data to train the machine learning models with different algorithms to predict ASD
diagnosis in the preterm group. Shapley additive explanations (SHAP) values assess the effect of each
feature on the model performance.

Table 1. Characteristics of the analyzed participants.

Cohort		SPARK (version 9)		SSC
		ASD	**Non-ASD**	**ASD**
Phenotype analysis	Number of samples	74,217	/	1,636
	Preterm in ASD (%)	12.4%	/	9.6%

		Preterm		9,196	2,706	157
			Extremely preterm (GA <28 weeks)	699 (8%)	109 (4%)	/
			Very preterm (GA 28-31weeks)	987 (11%)	274 (10%)	2 (1%)
			Moderate preterm (GA 21-33 weeks)	1,274 (14%)	372 (14%)	11 (7%)
			Late preterm (GA 34-36 weeks)	5,659 (62%)	1,754 (65%)	144 (92%)
			Unknown GA	577 (6%)	197 (7%)	/
			Male:Female	6,860:2,336	1,358:1,348	139:18
		Term		65021	/	1,479
			Male:Female	48,069:16,952	/	1,270:209
Genetic analysis	De novo variant (WGS)	Preterm		309 (10.2%)	164	137 (9.4%)
			Male:Female	257:52	90:74	121:16
		Term		2,728	/	1,313
			Male:Female	2,172:556	/	1,129:184
	De novo variant (WES)	Preterm		697 (10.8%)	210	/
			Male:Female	563:134	119:91	/
		Term		5,747	/	/
			Male:Female	4,557:1,190	/	/
	Inherited variant	Preterm		310 (10.2%)	165	/
			Male:Female	258:52	90:75	/
		Term		2,742	/	/
			Male:Female	2,182:560	/	/
	PRS	Preterm		305 (10.1%)	161	155 (9.7%)
			Male:Female	252:53	86:75	137:18
		Term		2,702	6,472	1,435
			Male:Female	2,134:568	2,817:3,655	1,236:199
Machine learning		Preterm		279	150	/
			Male:Female	230:49	81:69	/
		Term		2,601	1,664	/
			Male:Female	2,064:537	799:865	/

/ Mark as data were not analyzed. GA = Gestational age at birth. The % number labeled after sample

size of preterm in each analysis represents the frequency of preterm birth among ASD individuals in

that analysis part.

We performed analysis on nine available diagnostic categories recorded in the basic medical

screening dataset in SPARK phenotype database version 9, involving behavior, development, mood,

growth, birth, eating habits (eat), neurological conditions (neuro), visual and auditory impairments

(visual), and sleep (details of diagnostic categories are described in Additional file 1: Table S1). For

each category, we assigned a binary variable indicating the presence or absence of conditions within

that category, rather than counting the number of specific diagnoses. The prevalence of all diagnostic

categories analyzed was higher in ASD-preterm compared to ASD-term (Figure 2A). Specifically, ASD-

preterm had higher odds ratio (OR) for all diagnostic categories, with the highest being for birth and

growth diagnoses (ORs=2.18 [95% CI 1.97–2.40] and 2.18 [95% CI 2.06–2.31], respectively).

Additionally, preterm birth was associated with a modestly increased likelihood of other behavioral

diagnoses compared to term in the ASD group (OR=1.19 [95% CI 1.14–1.25]). The results remained

consistent after adjusting for sex, age, and family linkage using GEE models (Additional file 1: Table

S8). We also observed significantly different prevalences of diagnostic categories (χ^2 test with FDR-

adjusted $p<0.001$ for all categories) when we considered different sub-groups of preterm birth

(Additional file 1: Figure S1A). Furthermore, we identified linear trends across different preterm

stages, with groups of lower gestational age showing a higher prevalence in growth, eating, neuro,

and visual diagnostic categories (Kendall's tau test, FDR-adjusted $p=0.04$). Almost all the preterm sub-

groups had a higher prevalence of diagnostic categories compared to the term stage (FDR-adjusted p

of the post-hoc comparisons of χ^2 test are in Additional file 1: Table S9)

Then, we analyzed multimorbidity, indicated as the number of concurrent diagnostic categories

(Additional file 1: Table S1) among the ASD individuals, revealing that ASD-preterm exhibited a higher

likelihood of the higher number of concurrent morbidities compared to ASD-term (Figure 2B, χ^2 test

with $p<2.2\times10^{-16}$; ORs are recorded in Additional file 1: Table S10). In ASD, preterm sub-groups

showed differences in the burden of multimorbidity (Additional file 1: Figure S1B, χ^2 test with

$p<2.2\times10^{-16}$), in which extremely and moderate preterm subgroups exhibited a significantly higher

burden of multimorbidity with >=5 diagnoses compared to late preterm (Additional file 1: Table S11,

post-hoc test of χ^2 test with FDR-adjusted $p=1.6\times10^{-5}$, 0.02 respectively). For diagnostic categories

with more than two specific diagnoses, we found a positive linear correlation between the number

of specific diagnoses, i.e., multimorbidity, and the odds ratio of preterm versus term, except for

birth-related issues (Additional file 1: Figure S1C). This indicated that preterm ASD individuals tend to

have more specific diagnoses within categories as well as across categories than term ASD

individuals.

Next, we analyzed quantitative measures for overall behavioral challenges and specific symptom

domains. We observed significant differences between ASD-preterm and ASD-term (2-sided

Wilcoxon rank sum test with FDR adjustment), although the large sample size may amplify the

differences (Figure 2C). ASD-preterm had increased severity of behavioral challenges (CBCL score for

1-5y, p=1.4×10^{-3}; for 6-18y, p=0.0043), developmental coordination disorder (DCDQ final score,

p=2.5×10^{-21}), repetitive behaviors (RBS-R score, p=6.7×10^{-34}), and social communication skills (SCQ

score, p=1.4×10^{-20}), as well as lower IQ scores (p=0.02). Comparing different sub-groups of preterm

birth, we found that extremely preterm has the lowest DCDQ final score compared to other stages

(2-sided Wilcoxon rank sum test, FDR-adjusted p-values are 0.003, 0.002, and 2.7×10^{-5} when

compared to very preterm, moderate preterm, and late preterm, respectively) (Additional file 1:

Figure S2).

Figure 2. The phenotype comparison between preterm and term with ASD in the SPARK version 9

cohort. Color bars are the same across three panels and shown at the bottom of panel A. A.

Prevalence and odds ratio with 95% confidence interval (CI) of diagnostic categories. The detailed

outcomes in each diagnostic category are described in Table S1. The exact prevalence values are

labeled on the top of the bars. ORs are given among ASD individuals born preterm vs term and

recorded in Table S8. B. Distribution of the number of multimorbidities, defined as the total number

of diagnostic categories that appear in individuals. ORs with 95% CI are given among ASD individuals

born preterm vs term when focusing on each multimorbidity number and recorded in Table S10. C.

Differences in Child Behavior Checklist (CBCL) t-score for 1 to 5 and 6 to 18 years of age,

Developmental Coordination Disorder Questionnaire (DCDQ), Repetitive Behavior Scale-Revised

(RBS-R) score, Social Communication Questionnaire (SCQ) and Full-Scale IQ (Fsiq) among ASD

individuals born preterm and term. Significance was assessed using the 2-sided Wilcoxon rank sum

test with the FDR-adjusted p-values marked in the plots as 0-0.001***, 0.001-0.01**, 0.01-0.05* or

NS (non-significant difference).

To complement our analyses within the ASD individuals, we analyzed if there were any differences

within preterm birth for the same phenotype measures. The ASD-preterm had more severe

outcomes in comparison to non-ASD-preterm with increased severity with lower gestational age

(Additional file 1: Figure S3A-B, S4). The developmental diagnostic category had the highest

prevalence (72%) in the ASD-preterm group, resulting in 8.8 OR (95% CI 7.9–9.7) when compared to

non-ASD-preterm (Additional file 1: Table S12). Also, ASD-preterm group was seven times as likely

(OR = 7.0, 95% CI 5.4–9.4) to have five or more multimorbidities than non-ASD-preterm group

(Additional file 1: Table S13). For quantitative measures, the ASD-preterm group had statistically

significantly higher SCQ final scores compared to the non-ASD-preterm group (2-sided Wilcoxon rank

sum test, $p<2.2\times10^{-16}$) (Additional file 1: Figure S3C).

ASD-preterm and term comparisons within the SSC cohort also showed a higher prevalence of eating

and growth problems (OR=2.58 [95% CI 1.79–3.68], and 2.02 [95% CI 1.06–3.58] respectively;

Additional file 1: Table S14), and a similar trend towards having more multimorbidity compared to

ASD-term (Additional file 1: Figure S5A-B, χ^2 test p=0.045; Additional file 1: Table S15). No statistically

significant differences were observed in the quantitative measures (Additional file 1: Figure S5C).

Genetic variants comparison across ASD and prematurity

To investigate the burden of de novo variants, we analyzed available genome sequencing (GS) and

exome sequencing (ES) data from SPARK and SSC. The population analyzed for GS included 310 ASD-

preterm, 2,742 ASD-term, and 165 non-ASD-preterm individuals. The ES dataset contained 697 ASD-

preterm, 5,747 ASD-term, and 210 non-ASD-preterm individuals. We did not observe any significant

difference in DNV event rate or distribution of DNV numbers between ASD-preterm and ASD-term

(Figure 3A, Additional file 1: Figure S6A), or between ASD-preterm and non-ASD-preterm derived

from GS (Figure 3D, Additional file 1: Figure S6B), even when analyzing only the exonic region

(Additional file 1: Figure S7A-B). For the simplex family subset, no differences were observed

between preterm and term ASD probands (Additional file 1: Figure S8A). Similarly, no statistically

significant differences were found comparing de novo burden from GS in 137 ASD-preterm and 1,313

ASD-term in the SSC (Additional file 1: Figure S7C).

When analyzing DNV event rates obtained from ES data [8] from SPARK, no statistically significant

differences were found between ASD-preterm and ASD-term (Figure 3B, Additional file 1: Figure

S6C), even when restricted to probands in simplex families (Additional file 1: Figure S8B). However,

ASD-preterm individuals had more exonic DNVs (p=0.005), exonic DNVs on NDD genes (p=0.024), and

LOF affecting NDD genes (p=0.018) than non-ASD-preterm (Figure 3E, Additional file 1: Figure S6D).

We stratified the ASD-preterm and non-ASD-preterm by gestational age preterm subgroups and

observed a similar trend in both the moderate and late preterm groups. However, due to the limited

sample size, a statistically significant difference between ASD-preterm and non-ASD-preterm was

only detected in the event rate of DNVs in NDD genes in the moderate preterm group (p=0.02) and in

both overall DNV and DNV in NDD genes in the late preterm group (p=0.002 and 0.04, respectively).

Interestingly, for extremely to very preterm stages, the event rates of DNV were numerically lower in

ASD compared to non-ASD individuals, even though this difference was not statistically significant

(Additional file 1: Figure S9).

We also investigated the rates of inherited variants, focusing on those affecting NDD genes and

protein-coding regions. From 4,974 individuals with phenotype information, we did not observe

statistically significant differences between ASD-preterm and ASD-term nor between ASD-preterm

and non-ASD-preterm, although ASD-preterm tend to have a numerically higher rate of rare

inherited variants (Figure 3C, 3F, Additional file 1: Figure S6E, S6F). No differences between preterm

and term ASD probands in simplex families as well (Additional file 1: Figure S8C).

Figure 3. Association between genetic variant burden and subgroups with varying preterm birth and ASD status in the SPARK cohort. In ASD individuals, event rates of rare de novo variants (DNV) identified through genome sequencing (A) and exome sequencing (B), and inherited variants on dominant and recessive NDD genes identified through genome sequencing (C) were calculated. In preterm individuals, event rates of de novo variants identified through genome sequencing (D) and exome sequencing (E), and inherited variants in dominant and recessive NDD genes identified through genome sequencing (F) were calculated. Rare DNVs were filtered with AF<0.001, and rare inherited variants were filtered with AF<0.001 on dominant genes and AF<0.01 on recessive genes. Data are presented as mean values ± standard errors as error bars. The GEE model with Poisson family and sex covariate was used to compute the p-values to assess the differences in variant count between groups.

To further evaluate whether the greater multimorbidity is associated with increased DNV burden, and whether multimorbidity and DNV burden are jointly associated with the increased likelihood of ASD and preterm, we computed GEE models (Additional file 1: Table S16) and found that multimorbidity is positively correlated with GS LOF (p=0.037), GS LOF on NDD genes (p=5.3×10^{-06}) and all types of ES DNV burden (p=1.1×10^{-05}, 1.9×10^{-09}, 6.6×10^{-14} and <2.2×10^{-6} for DNV, LOF, DNV on NDD genes and LOF on NDD genes respectively) across all individuals. Stratified by preterm and ASD status, we observed this positive correlation pattern in ASD-term group for ES DNV (p=0.009), ES DNV

on NDD genes (p=0.013) and LOF on NDD genes (p=0.004), as well as in ASD-preterm group for ES

LOF on NDD genes (p=0.013) (Additional file 1: Figure S10). However, except for GS DNV on NDD

genes, there is no interaction between DNV burden and multimorbidity performing on ASD or

preterm outcomes.

ASD Polygenic risk score and association with preterm status

We calculated ASD PRS for individuals in the SPARK cohort using the most comprehensive GWAS on

ASD as source data [10]. There was no significant difference in the distribution of PRS between the

ASD-preterm and ASD-term groups (even restricted to simplex family probands) nor between ASD-

preterm and non-ASD-preterm (Figure 4A). As expected, ASD individuals had higher PRS compared to

non-ASD individuals in the whole cohort displaying the usability of the PRS (2-sided Wilcoxon rank

sum test, p=6.7×10^{-13}) (Figure 4A). The PRS explained 9.8% (McFadden Pseudo-r^2) variance of ASD

diagnosis in the SPARK cohort. Additionally, after adjusting for sex and population ancestry (as

indicated by principal components [PC]) in a GEE logistic model, we confirmed that there was no

independent association between preterm birth and PRS (in ASD population), or between ASD

diagnosis and PRS (in preterm population). The statistically non-significant association between

preterm birth and PRS (in ASD population) was replicated in the SSC cohort, and same for simplex

family probands in SPARK (Additional file 1: Figure S11). Furthermore, we computed a full GEE

logistic model for ASD diagnosis within European populations, showing that male sex, preterm birth,

and higher PRS were all positively associated with ASD diagnosis (p<2×10^{-16}, <2×10^{-16} and 2.2×10^{-12},

respectively) (Figure 4B). In this model for the SPARK cohort, the predicted probability of an ASD

diagnosis was almost 90% for preterm-born males, with the highest PRS (Figure 4C). Then, we

included the interaction between preterm status and PRS in the full GEE logistic model, observing a

significant association between this interaction and ASD diagnosis (p=0.017).

Figure 4. The association of polygenic risk score (PRS) with delivery term and ASD condition in SPARK cohort. A. The distribution of standardized PRS in groups with different delivery terms and ASD diagnosis. Statistical significance was assessed using the 2-sided Wilcoxon rank sum test with the p-value marked in the plots as 0-0.001*** or NS (statistically non-significant difference). B. Coefficient plot for the GEE logistic model [ASD(y/n) ~ sex(m/f) + Preterm status(y/n) + Standardized PRS] with family ID as a clustering variable, displaying the estimated coefficients for each variable. Positive coefficients suggest an increase in the likelihood of ASD associated with the variable, while negative coefficients indicate a decrease. Error bars represent 95% CI. C. Visualized effect plot of GEE model, which shows average predicted probabilities of ASD diagnosis for specific levels of variables, with color region around the line showing 95% CI.

501 Predictive model for ASD within preterm births

503 Lastly, we investigated the potential of ML models to identify those preterm infants with a high

504 likelihood of ASD from information present at birth by combining clinical and available genetic data.

The model was developed and tested using a study population with preterm individuals classified

into ASD (n=279) and non-ASD (n=150). For features used in the prediction model, we also

considered Combined Annotation Dependent Depletion (CADD) scores, which assess the potential

impact (i.e., deleterious or benign) of genetic variants on the function of genes and were available

for most of the DNVs. We applied Recursive Feature Elimination (RFE) and a correlation threshold of

0.7 to select 13 features, including clinical features (sex, condition of birth complications, gestational

age, insufficient oxygen at birth) and genomic features (number of several types of variants, CADD

scores and standardized ASD-PRS) (Additional file 1: Figure S12A, Table S6). We used three algorithms

to train the models (Table 2), of which the XGBoost model exhibited the highest area under the

receiver operating characteristic curve (AUROC), at 0.65. The model accurately identified 69% (95%

CI 0.644–0.733) ASD diagnoses in the preterm, with a sensitivity of 0.81, specificity of 0.47, and F1-

score of 0.77. We also trained a model using the same set of features on all individuals, including

both preterm and term (assuming a gestational age of 40 weeks for terms), and despite the sample

size (1814 non-ASD and 2880 ASD) being approximately 10 times larger than that of the preterm

model, the model performance was comparable (XGBoost with accuracy = 0.69 [95% CI 0.672–

0.699]; AUC = 0.68; F1-score = 0.76; Additional file 1: Table S17).

The first three XGBoost models within the 10-fold training (Additional file 1: Figure S12B) were

selected to visualize feature effects for the best-performing model for ASD within preterm births. The

feature importance varied slightly across the training XGBoost models with sex, PRS, and CADD score

being the most important features (Additional file 1: Figure S12C, S12E, S12G). Using SHAP values to

characterize the impact of each feature on the model's output for specific individuals, we found that

sex had the highest significant impact on the model's predictions, whereas being male had a positive

impact on the model's prediction. Furthermore, we demonstrate that lower gestational age, more

autosomal exonic DNVs, more dominant inherited variants, more LOF variants, the presence of birth

530 complications, and insufficient oxygen at birth drove the model towards ASD prediction result

531 (Additional file 1: Figure S12D, S12F, S12H).

533 **Table 2. Performance metrics of machine learning models used to predict ASD diagnosis in preterm**
534 **individuals.**

Algorithm	Accuracy	95% CI	AUC	Sensitivity	Specificity	F1-score
XGBoost	0.69	(0.64, 0.73)	0.65	0.81	0.47	0.77
Random forest	0.67	(0.63, 0.72)	0.63	0.86	0.33	0.77
SVM	0.70	(0.66, 0.75)	0.62	0.84	0.46	0.79

Discussion

Here, we conducted a comprehensive analysis of phenotypic differences using larger cohorts, as well

as genotypic differences, which have been explored in only a few studies among preterm and term-

birth ASD individuals. We conclude that preterm-born ASD individuals have more diagnoses across

different categories and a number of co-occurring diagnoses but similar genetic landscapes when

investigating sequence-level rare DNVs and inherited variants as well as a polygenic load for ASD

compared with ASD-term. Our analysis of preterm individuals with and without ASD showed similar

results for the phenotype comparisons but inconsistent findings for the genetic burden. The largest

de novo dataset derived from ES showed that the ASD-preterm had a higher exonic DNV event rate

than the non-ASD-preterm; however, we did not validate this finding in the de novo dataset from

GS. Additionally, the male with preterm status and higher polygenic load faces a higher likelihood of

ASD when considering these features together. Furthermore, our ML model demonstrated potential

for predicting ASD diagnosis in preterm children by integrating phenotype and genetic information.

Our results provide evidence that genetic factors play a role in emerging ASD in preterm birth, but

the environmental stressor of being preterm potentially contributes to the severity and

multimorbidity.

Previous research has reported numerous but inconsistent findings regarding phenotypic disparities

between ASD preterm and term individuals [20,22], while limited research has focused on

investigating the genetic link of ASD in prematurity. Unlike most phenotypic comparisons that

concentrate on specific diagnostic outcomes [21,22], we first grouped the various conditions into

nine broader diagnostic categories. Our results indicate that children with both preterm birth and

ASD exhibit a higher prevalence of diagnoses within these categories and a higher rate of

multimorbidity across different diagnostic categories. To note, we did not replicate all the observed

associations in SSC cohort, which had mostly late preterm category for the GA and more restrictive

recruitment criteria, which could explain the lack of replication. Previous studies have found that

both preterm birth and ASD are associated with adverse symptoms. For instance, preterm infants

are independently inherently prone to multimorbidity and severe health complications affecting

multiple organs and systems [17,53,54], such as visual and auditory impairments [55], epilepsy [56],

ADHD [18], and other psychiatric disorders [19]. Additionally, individuals with ASD experience a

higher burden of co-occurring medical conditions [57]. Our study further supports the hypothesis

that preterm acts as an environmental liability factor, potentially influencing some of the

heterogeneity and higher comorbidity rates observed in ASD.

After stratifying preterm based on gestational age, we observed that those born with lower

gestational age tend to have more severe outcomes, which is in line with the dose-effect reported in

prematurity, where the likelihood of developmental issues increases with decreasing gestational age

[54]. This effect is also reflected in the potentially increasing complexity of multimorbidity among

groups with lower gestational age [17]. Additionally, we showed significantly more severe symptom

levels, as measured by different standardized questionnaires and cognitive tests, in ASD-preterm,

consistent with previous studies as well as general research comparing preterm and term birth

[18,58–60]. It is important to note that with large sample sizes, even very small differences can

become statistically significant. In SSC cohort, with over 90% of preterm individuals being late

preterm, thus replication of results was limited. Therefore, the results should be interpreted with

caution especially for clinical utility.

In idiopathic ASD, heritability is estimated to be approximately 80% [6], but in preterm born,

environmental factors account for 60% of the variation in gestational age [61]. Our findings suggest

that genetic factors underlie, at least partly, the ASD diagnosis even in preterm, but that the

complex phenotypic presentation, including multimorbidity, could be due to the environmental

stressor of being preterm. Specifically, we did not observe significant differences in DNV numbers

between preterm and term ASD individuals. We did observe suggestive evidence that DNV burden

could be higher in ASD-preterm compared with non-ASD-preterm, however, the finding was

inconsistent in the validation cohort with a smaller sample size and after stratifying by preterm

stages. We speculate that this may be indicative of distinct underlying genetic mechanisms for ASD

across different preterm sub-groups. Across preterm, in light of previous reports showing that ASD

has a higher DNV burden than non-ASD [7], we suspect that some DNVs specifically affect ASD

liability but not prematurity, or some DNVs could be liability factors for both ASD and prematurity.

Limited research indicated a higher DNV burden in overall preterm newborn genomes and primarily

in genes related to embryonic brain development; however, the study did not consider ASD or

another behavioral diagnosis in preterm infants [23], especially ASD also susceptibility to brain

development-related genes [62]. For the lack of differences in DNV burden observed between

preterm and term in ASD, one hypothesis is that some DNVs contributing to ASD have global effects

on overall physiology and also contribute to prematurity. In this situation, those DNVs could possibly

increase the likelihood of both preterm birth and ASD with multimorbidity. Furthermore, it remains

to be clarified to what extent prematurity acts as an environmental liability factor to ASD when

counting in genetic background.

Although GWAS studies of prematurity have identified variations in maternal and fetal genes

separately [63,64], few have examined the impact of rare inherited variants. Our study did not find a

difference in the burden of rare inherited variants between ASD-preterm and ASD-term individuals.

This can be partially explained by the fact that the maternal genome influences prematurity more

than the fetal genome [15]. Additionally, we have perhaps overlooked shared genetic factors that

potentially contribute to both preterm birth and neurodevelopment when we analyze individuals

with either ASD or prematurity. For example, variants at *AGTR2* and *ADCY5* genes in mothers have

been associated with gestational duration and preterm birth, and infants show around half of effect

size by sharing one of the maternal allele by descent [65]. Notably, these two genes are also known

ASD-associated genes [40].

Although we did not find an overall association between ASD PRS and prematurity, we show

intriguing findings that in the SPARK cohort, those with the highest PRS could have a higher

likelihood of ASD, especially in preterm infants and boys. Even after including the interaction

between preterm status and PRS, these features maintained a significant association with ASD

likelihood, and the interaction itself was significantly associated with ASD diagnosis. The lowest PRS

in preterm males still reached a 75% predicted probability of ASD, emphasizing the prematurity

effect on ASD liability and the greater susceptibility in males, while also indicating a potential sample

bias towards ASD in our analysis. Again, these findings need validation in the general population,

especially as a prior study by Cullen et al. found no evidence of an interaction effect between ASD

polygenic score and gestational age at birth on cognition [16]. However, it is important to note that

the cognitive difficulty they measured is only one of the outcomes that do not imply an ASD

diagnosis, and the model they used also included socio-economic status as a covariate.

In addition to genetic factors, widespread alterations in brain development associated with preterm infants may contribute to the increase in ASD likelihood. Previous studies have indicated that reduced structural brain asymmetry and poor brain development during neonatal life may increase the liability of ASD in preterm infants [66,67]. Even in preterm children exhibiting similar ASD traits during childhood, distinct etiological trajectories have been observed involving variations in neonatal cerebellar volume and developmental delay [68].

Not all preterm infants develop ASD [69], still we demonstrate that when genetic factors are combined with the environmental risk of preterm birth, preterm children face a highly elevated likelihood of ASD diagnosis. Recognizing the limitations of traditional statistical models in capturing nonlinear interactions between features, we developed an ML model to predict ASD diagnosis in preterm children at birth. Unlike previous ASD prediction models that rely on developmental trajectories or typical characteristics collected as children grow [26,30,70], our ML model utilized only information available at birth, integrating phenotype and genetic information. Moreover, most previous models are based on the general population [26,70], limiting their applicability to preterm infants. However, it is necessary to build prediction models tailored specifically for preterm infants due to the heterogeneity of ASD phenotypes [1], and preterm ASD children may exhibit specific phenotypes compared to term ASD children [19]. Although our ML model did not achieve significantly higher performance, achieving 69% accuracy with a small sample size and few features demonstrates the feasibility and efficacy of integrating phenotype and genetic information for ASD prediction. There is still substantial room for improvement in the model performance. Increasing the sample size and adding more features associated with preterm birth and ASD (e.g., maternal age, prenatal exposure, and fetal birth weight) would benefit the prediction model construction. Other features like intubation in the delivery room, family language, parental education, Infection, and ventilation have also been found to have predictive ability for cognitive outcomes in very preterm

infants [30]. It is important to note that we cannot identify the causal relationships between features

selected by the model and ASD diagnosis. Still, we suggest that these features could potentially

enhance prediction models in the future.

Our study has several limitations. Firstly, two cohorts are ASD-focused, and the non-ASD groups are

mainly relatives of ASD probands, thus introducing sample bias to ASD and potentially

underestimating genetic differences between the groups. Given the high heritability estimation in

ASD, siblings with a closer relationship with ASD have a higher relative risk ratio for ASD [4].

Secondly, we did not stratify the analyses by sex due to the limited sample size, potentially

overlooking sex-specific differences. Thirdly, we focused here only on the sequence level variation,

incorporating more types of genetic variations will be the next step. Additionally, our exploration of

genetic factors primarily focused on average population-level associations and NDD genes,

potentially overlooking genetic effects beyond the currently known ASD-associated genes and

variants that may contribute to the elevated likelihood of ASD in preterm children. Previous studies

have pointed out the genetic association between preterm and ASD, such as common genetic

variants linking abnormalities in the gut-brain axis with both conditions [71]. Finally, the lack of

comparability of SSC with the SPARK cohort may reflect both reduced statistical power and cohort

differences. The SPARK cohort collected participants with different family structures and highly

heterogeneous clinical severity. While the SSC cohort with a smaller sample size excluded probands

with conditions might reduce the validity of diagnoses (e.g., known genetic syndromes, significant

perinatal complications, and low mental age). In particular, the distribution of gestational age differs

in two cohorts, and more than 90% of preterm in SSC are late preterm. Also, the sample size is low

for some of the analyzed groups despite similar percentages of preterm in ASD in the two cohorts.

Further validation in larger preterm cohorts or general population-based samples is a key future

direction. We believe that combining genetic features and more detailed phenotypic information will

help to explain further why some preterm children have ASD while others do not.

Conclusion

In conclusion, we demonstrate that ASD genetic liability is similar in ASD-term and ASD-preterm,

suggesting that even within preterm, genetic factors play an important role in etiology. Our study did

not find evidence of a link between genetic factors and preterm birth in ASD. However, our findings

suggest that preterm birth would exacerbate the severity of outcomes in ASD individuals, and this

difference may be driven more by environmental factors. As we observed some differences in the

rate of ES DNV in preterm individuals compared between ASD and non-ASD, we only suggest that

genetic factors may increase the likelihood of a preterm child getting an ASD diagnosis and the

diagnosis is not modified by the interaction between multimorbidity and DNV burden. Through the

development of our ML model, we demonstrate that integrating phenotype and genetic information

is feasible and holds promise for the early prediction of ASD in preterm children at birth. Our study

provides insights into the phenotypic characteristics of ASD preterm individuals. We suggest that

health screening for preterm birth infants should incorporate the collection of genetic data, as it

better supports early clinical identification of ASD and can aid in the guidance of early intervention

strategies.

List of abbreviations

ASD: Autism Spectrum Disorder

SPARK: Simons Foundation Powering Autism Research for Knowledge

SSC: Simons Simplex Collection

GS: Genome sequencing

ES: Exome sequencing

GEE: Generalized Estimating Equations

PRS: Polygenic Risk Score

DNV: De Novo Variants

CNV: Copy number variation

GWAS: Genome-Wide Association Studies

NDD genes: Neurodevelopmental Disorders-Related Genes

ML: Machine Learning

CBCL: Child Behavior Checklist

DCDQ: Developmental Coordination Disorder Questionnaire

RBS-R: Repetitive Behavior Scale-Revised

SCQ: Social Communication Questionnaire

Fsiq: Full-Scale Intelligence Quotient

AB: Allele Balance

LOF: Loss-of-Function

CADD: Combined Annotation Dependent Depletion

PCA: Principal Component Analysis

PC: Principal Components

CI: Confidence Interval

RFE: Recursive Feature Elimination

XGBoost: Extreme Gradient Boosting

RF: Random Forest

SVM: Linear Support Vector Machine

AUROC: Area Under the Receiver Operating Characteristic Curve

SHAP: SHapley Additive exPlanations

GA: Gestational Age at Birth

OR: Odds Ratio

FDR: False Discovery Rate

Additional files

735   Additional file 1: Supplementary Figures S1–S12 and Supplementary Tables S1–S17. (PDF 4,198 kb)

736   Additional file 2: Neurodevelopmental disorder-related gene list used in this study. (XLS 65 kb)

Declarations

Ethics approval and consent to participate: Ethical approval for the data collection and informed

consent were obtained from the participants within the SPARK and SSC projects. The Swedish Ethical

Committee approved this study and data analysis in Sweden (dnr 2020-00400).

Consent for publication: Not applicable.

Availability of data and materials: The data that support the findings of this study are available from

the Simons Foundation Autism Research Initiative (SFARI, https://www.sfari.org/resource/sfaribase)

but restrictions apply to the availability of these data, which were used under license for the current

study, and so are not publicly available. Data are however available from the authors upon

reasonable request and with permission of SFARI. The R scripts used to perform the main analysis

reported in this manuscript are available on GitHub (https://github.com/Tammimies-

Lab/AutismPreterm_Zhang).

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by grants from the Swedish Foundation for Strategic Research

(FFL18-0104), the Swedish Research Council (2017-01660_VR, 2017-03043_VR, 2023-02111_VR ,

Authors' contributions: Y.Z. and K.T. designed the study and planned the analyses. Y.Z. performed the

analyses. Y.A. provided support for the analysis. S.S., U.Å, and K.T. provided supervision and support

for the analysis. Y.Z. wrote the first draft with feedback from K.T. All authors provided critical

feedback and helped shape the research, analysis, and the final manuscript.

Acknowledgements: We thank all the participants of SPARK and SSC cohorts and Simons Foundation

for access of the data. The computations were performed using resources provided by the National

Academic Infrastructure for Supercomputing in Sweden (NAISS) through Uppsala Multidisciplinary

Center for Advanced Computational Science (UPPMAX). Furthermore, research reported in this

publication was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human

Development of the National Institutes of Health under Award Number R01HD113669. The content

is solely the responsibility of the authors and does not necessarily represent the official views of the

National Institutes of Health.

Reference

1. Rosen NE, Lord C, Volkmar FR. The Diagnosis of Autism: From Kanner to DSM-III to DSM-5 and
Beyond. J Autism Dev Disord. 2021;51:4253–70.

2. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. Nat
Rev Dis Primers. 2020;6:5.

3. Carlsson T, Molander F, Taylor MJ, Jonsson U, Bölte S. Early environmental risk factors for
neurodevelopmental disorders – a systematic review of twin and sibling studies. Dev Psychopathol.
2021;33:1448–95.

4. Havdahl A, Niarchou M, Starnawska A, Uddin M, van der Merwe C, Warrier V. Genetic
contributions to autism spectrum disorder. Psychol Med. 2021;51:2260–73.

5. Ruzzo EK, Pérez-Cano L, Jung J-Y, Wang L-K, Kashef-Haghighi D, Hartl C, et al. Inherited and De Novo
Genetic Risk for Autism Impacts Shared Networks. Cell. 2019;178:850-866.e26.

6. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of Genetic and
Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry. 2019;76:1035.

7. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo
coding mutations to autism spectrum disorder. Nature. 2014;515:216–21.

8. Zhou X, Feliciano P, Shu C, Wang T, Astrovskaya I, Hall JB, et al. Integrating de novo and inherited
variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nat Genet.
2022;54:1305–19.

9. Wilfert AB, Turner TN, Murali SC, Hsieh P, Sulovari A, Wang T, et al. Recent ultra-rare inherited
variants implicate new autism candidate risk genes. Nat Genet. 2021;53:1125–34.

10. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common
genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431–44.

11. Loughnan RJ, Palmer CE, Makowski C, Thompson WK, Barch DM, Jernigan TL, et al. Unique
prediction of developmental psychopathology from genetic and familial risk. Child Psychology
Psychiatry. 2022;63:1631–43.

12. Antaki D, Guevara J, Maihofer AX, Klein M, Gujral M, Grove J, et al. A phenotypic spectrum of
autism is attributable to the combined effects of rare variants, polygenic risk and sex. Nature
genetics. 2022;54:1284–92.

13. Crump C, Sundquist J, Sundquist K. Preterm or Early Term Birth and Risk of Autism. Pediatrics.
2021;148:e2020032300.

14. Persson M, Opdahl S, Risnes K, Gross R, Kajantie E, Reichenberg A, et al. Gestational age and the
risk of autism spectrum disorder in Sweden, Finland, and Norway: A cohort study. Fassett MJ, editor.
PLoS Med. 2020;17:e1003207.

15. Svensson AC, Sandin S, Cnattingius S, Reilly M, Pawitan Y, Hultman CM, et al. Maternal Effects for
Preterm Birth: A Genetic Epidemiologic Study of 630,000 Families. American Journal of Epidemiology.
2009;170:1365–72.

16. Cullen H, Selzam S, Dimitrakopoulou K, Plomin R, Edwards AD. Greater genetic risk for adult
psychiatric diseases increases vulnerability to adverse outcome after preterm birth. Sci Rep.
2021;11:11443.

17. Heikkilä K, Metsälä J, Pulakka A, Nilsen SM, Kivimäki M, Risnes K, et al. Preterm birth and the risk
of multimorbidity in adolescence: a multiregister-based cohort study. The Lancet Public Health.
2023;8:e680–90.

18. Allotey J, Zamora J, Cheong-See F, Kalidindi M, Arroyo-Manzano D, Asztalos E, et al. Cognitive,
motor, behavioural and academic performances of children born preterm: a meta-analysis and
systematic review involving 64 061 children. BJOG. 2018;125:16–25.

19. Johnson S, Marlow N. Preterm Birth and Childhood Psychiatric Disorders. Pediatric Research.
2011;69:11R-18R.

20. Joseph RM, Lai ER, Bishop S, Yi J, Bauman ML, Frazier JA, et al. Comparing autism phenotypes in
children born extremely preterm and born at term. Autism Research. 2023;16:653–66.

21. Leoni M, Vanes LD, Hadaya L, Kanel D, Dazzan P, Simonoff E, et al. Exploring cognitive, behavioral
and autistic trait network topology in very preterm and term-born children. Front Psychol.
2023;14:1119196.

22. Luu J, Jellett R, Yaari M, Gilbert M, Barbaro J. A Comparison of Children Born Preterm and Full-
Term on the Autism Spectrum in a Prospective Community Sample. Front Neurol. 2020;11:597505.

23. Li J, Oehlert J, Snyder M, Stevenson DK, Shaw GM. Fetal de novo mutations and preterm birth.
Williams SM, editor. PLoS Genet. 2017;13:e1006689.

24. Wong HS, Wadon M, Evans A, Kirov G, Modi N, O'Donovan MC, et al. Contribution of de novo and
inherited rare CNVs to very preterm birth. J Med Genet. 2020;57:552–7.

25. Everett SS, Bomback M, Sahni R, Wapner RJ, Tolia VN, Clark RH, et al. Prevalence and Clinical
Significance of Commonly Diagnosed Genetic Disorders in Preterm Infants [Internet]. 2023 [cited
2024 Sep 20]. Available from: http://medrxiv.org/lookup/doi/10.1101/2023.07.14.23292662

26. Chen J, Engelhard M, Henao R, Berchuck S, Eichner B, Perrin EM, et al. Enhancing early autism
prediction based on electronic records using clinical narratives. Journal of Biomedical Informatics.
2023;144:104390.

27. Rajagopalan SS, Zhang Y, Yahia A, Tammimies K. Machine Learning Prediction of Autism Spectrum
Disorder From a Minimal Set of Medical and Background Information. JAMA Netw Open.
2024;7:e2429229.

28. Asif M, Martiniano HFMC, Marques AR, Santos JX, Vilela J, Rasga C, et al. Identification of
biological mechanisms underlying a multidimensional ASD phenotype using machine learning. Transl
Psychiatry. 2020;10:43.

29. Li D, Choque Olsson N, Becker M, Arora A, Jiao H, Norgren N, et al. Rare variants in the outcome
of social skills group training for autism. Autism Res. 2022;15:434–46.

30. Bowe AK, Lightbody G, Staines A, Murray DM, Norman M. Prediction of 2-Year Cognitive
Outcomes in Very Preterm Infants Using Machine Learning Methods. JAMA Netw Open.
2023;6:e2349111.

31. Feliciano P, Daniels AM, Green Snyder L, Beaumont A, Camba A, Esler A, et al. SPARK: A US Cohort
of 50,000 Families to Accelerate Autism Research. Neuron. 2018;97:488–93.

32. Fischbach GD, Lord C. The Simons Simplex Collection: A Resource for Identification of Autism
Genetic Risk Factors. Neuron. 2010;68:192–5.

33. Ng JK, Vats P, Fritz-Waters E, Sarkar S, Sams EI, Padhi EM, et al. de novo variant calling identifies
cancer mutation signatures in the 1000 Genomes Project. Human Mutation. 2022;43:1979–93.

34. Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, et al. Polygenic transmission
disequilibrium confirms that common and rare variation act additively to create risk for autism
spectrum disorders. Nature genetics. 2017;49:978–85.

35. Pedersen BS, Brown JM, Dashnow H, Wallace AD, Velinder M, Tristani-Firouzi M, et al. Effective
variant filtering and expected candidate variant yield in studies of rare human disease. npj Genom
Med. 2021;6:60.

36. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome
Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data.
Genome Res. 2010;20:1297–303.

37. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Research. 2010;38:e164–e164.

38. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and
predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila
melanogaster strain w ^{1118} ; iso-2; iso-3. Fly. 2012;6:80–92.

39. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect
Predictor. Genome Biol. 2016;17:122.

40. Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA, et al. SFARI Gene 2.0:
a community-driven knowledgebase for the autism spectrum disorders (ASDs). Molecular Autism.
2013;4:36.

41. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources
expert knowledge to establish consensus diagnostic gene panels. Nat Genet. 2019;51:1560–5.

42. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant call format
and VCFtools. Bioinformatics. 2011;27:2156–8.

43. Kochinke K, Zweier C, Nijhof B, Fenckova M, Cizek P, Honti F, et al. Systematic Phenomics Analysis
Deconvolutes Genes Mutated in Intellectual Disability into Biologically Coherent Modules. The
American Journal of Human Genetics. 2016;98:149–64.

44. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER: Database of
Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. The American Journal
of Human Genetics. 2009;84:524–33.

45. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to
the challenge of larger and richer datasets. GigaSci. 2015;4:7.

46. Hinrichs AS. The UCSC Genome Browser Database: update 2006. Nucleic Acids Research.
2006;34:D590–8.

47. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and
continuous shrinkage priors. Nat Commun. 2019;10:1776.

48. Halekoh U, Højsgaard S, Yan J. The R Package geepack for Generalized Estimating Equations. J Stat
Soft [Internet]. 2006 [cited 2024 May 7];15. Available from: http://www.jstatsoft.org/v15/i02/

49. Lüdecke D. ggeffects: Tidy Data Frames of Marginal Effects from Regression Models. Journal of
Open Source Software. 2018;3:772.

50. Gregorutti B, Michel B, Saint-Pierre P. Correlation and variable importance in random forests. Stat
Comput. 2017;27:659–78.

51. Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Soft. 2008;28:1–26.

52. Liu Y, Just A. SHAPforxgboost: SHAP Plots for "XGBoost" [Internet]. 2020. Available from:
https://github.com/liuyanguu/SHAPforxgboost/

53. Heikkilä K, Pulakka A, Metsälä J, Alenius S, Hovi P, Gissler M, et al. Preterm birth and the risk of
chronic disease multimorbidity in adolescence and early adulthood: A population-based cohort
study. Jacobsen R, editor. PLoS ONE. 2021;16:e0261952.

54. Johnson S, Marlow N. Growing up after extremely preterm birth: Lifespan mental health
outcomes. Seminars in Fetal and Neonatal Medicine. 2014;19:97–104.

55. Hirvonen M, Ojala R, Korhonen P, Haataja P, Eriksson K, Gissler M, et al. Visual and Hearing
Impairments After Preterm Birth. Pediatrics. 2018;142:e20173888.

56. Li W, Peng A, Deng S, Lai W, Qiu X, Zhang L, et al. Do premature and postterm birth increase the
risk of epilepsy? An updated meta-analysis. Epilepsy & Behavior. 2019;97:83–91.

57. Khachadourian V, Mahjani B, Sandin S, Kolevzon A, Buxbaum JD, Reichenberg A, et al.
Comorbidities in autism spectrum disorder and their etiologies. Transl Psychiatry. 2023;13:71.

58. Johnson S, Hollis C, Kochhar P, Hennessy E, Wolke D, Marlow N. Autism Spectrum Disorders in
Extremely Preterm Children. The Journal of Pediatrics. 2010;156:525-531.e2.

59. Schieve LA, Baio J, Rice CE, Durkin M, Kirby RS, Drews-Botsch C, et al. Risk for cognitive deficit in a
population-based sample of U.S. children with autism spectrum disorders: Variation by perinatal
health factors. Disability and Health Journal. 2010;3:202–12.

60. Zhu JL, Olsen J, Olesen AW. Risk for Developmental Coordination Disorder Correlates with
Gestational Age at Birth. Paediatric Perinatal Epid. 2012;26:572–7.

61. York TP, Eaves LJ, Lichtenstein P, Neale MC, Svensson A, Latendresse S, et al. Fetal and Maternal
Genes' Influence on Gestational Age in a Quantitative Genetic Analysis of 244,000 Swedish Births.
American Journal of Epidemiology. 2013;178:543–50.

62. Li C, Fleck JS, Martins-Costa C, Burkard TR, Themann J, Stuempflen M, et al. Single-cell brain
organoid screening identifies developmental defects in autism. Nature. 2023;621:373–80.

63. Solé-Navais P, Flatley C, Steinthorsdottir V, Vaudel M, Juodakis J, Chen J, et al. Genetic effects on
the timing of parturition and links to fetal birth weight. Nat Genet. 2023;55:559–67.

64. Liu X, Helenius D, Skotte L, Beaumont RN, Wielscher M, Geller F, et al. Variants in the fetal
genome near pro-inflammatory cytokine genes on 2q13 associate with gestational duration. Nat
Commun. 2019;10:3927.

65. Zhang G, Feenstra B, Bacelis J, Liu X, Muglia LM, Juodakis J, et al. Genetic Associations with
Gestational Duration and Spontaneous Preterm Birth. N Engl J Med. 2017;377:1156–67.

66. Eklöf E, Mårtensson GE, Ådén U, Padilla N. Reduced structural brain asymmetry during neonatal
life is potentially related to autism spectrum disorders in children born extremely preterm. Autism
Research. 2019;12:1334–43.

67. Padilla N, Eklöf E, Mårtensson GE, Bölte S, Lagercrantz H, Ådén U. Poor Brain Growth in Extremely
Preterm Neonates Long Before the Onset of Autism Spectrum Disorder Symptoms. Cereb Cortex.
2015;bhv300.

68. Hadaya L, Vanes L, Karolis V, Kanel D, Leoni M, Happé F, et al. Distinct Neurodevelopmental
Trajectories in Groups of Very Preterm Children Screening Positively for Autism Spectrum Conditions.
J Autism Dev Disord. 2024;54:256–69.

69. Hee Chung E, Chou J, Brown KA. Neurodevelopmental outcomes of preterm infants: a recent
literature review. Transl Pediatr. 2020;9:S3–8.

70. Amit G, Bilu Y, Sudry T, Avgil Tsadok M, Zimmerman DR, Baruch R, et al. Early Prediction of
Autistic Spectrum Disorder Using Developmental Surveillance Data. JAMA Netw Open.
2024;7:e2351052.

71. Sajdel-Sulkowska EM, Makowska-Zubrycka M, Czarzasta K, Kasarello K, Aggarwal V, Bialy M, et al.
Common Genetic Variants Link the Abnormalities in the Gut-Brain Axis in Prematurity and Autism.
Cerebellum. 2019;18:255–65.